Stock fact sheet · data as of
Alnylam Pharmaceuticals, Inc. (ALNY): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · High Growth
Is ALNY undervalued?
At 234.03 (close of 16 Oct 2026), ALNY trades 35% over the GLS average fair value of 173.82, with 2 of 7 models above the price. The stock earns none of the Wheel Score's Value points at this price. That is a statement about price against trailing fundamentals, not about the company's prospects - the Wall Street View and the Growth tab on the Quote page carry the forward numbers.
The 7 models disagree widely: Graham Number gives 37.24 while GLS Growth gives 371.24. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files ALNY under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for ALNY
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 37.24 | -84% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 343.01 | +47% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 149.63 | -36% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 371.24 | +59% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | 86.98 | -63% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | 161.23 | -31% | Eight years of compounded free cash flow: the price at which the business pays for itself |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 67.38 | -71% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.9453 | -100% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 347.23 | +48% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is average - ALNY passes 6 of the nine Piotroski tests, which passes the Sunday Scan's "6 or more" rule. The Financials tab on the Quote page shows which tests fail. The GLS Moat score is low at 4.7 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are high - ROIC 15.2%, ROE 39.8%, ROA 6.3% - with debt at 1.62 times equity and a free-cash-flow yield of 1.7%.
Alnylam Pharmaceuticals, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 92%, Givlaari 7%, Onpattro 1% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 1/10 on the GLS smart-money scales.
| Piotroski F-score | 6 / 9 | ROIC | 15.2% |
|---|---|---|---|
| GLS Moat | 4.7 / 10 | ROE | 39.8% |
| Debt / equity | 1.62 | ROA | 6.3% |
| Free-cash-flow yield | 1.7% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 1 / 10 |
Wheel Score 59: Fair
ALNY scores 59 out of 100 on the Wheel Score (Fair band, 50-64): a usable but unremarkable fit for the wheel strategy. The parts: Value 0/25, Health 13/20, Moat 7/15, Premium 20/20, Stability 19/20. Value (0/25) is where the points are missing.
Implied volatility is 58% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is 39,764 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 1.3M shares a day on a market cap of $31.3B, with a beta of 0.27 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 19 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 0 / 25 | -35% margin of safety | |
| Health | 13 / 20 | Piotroski 6/9 | |
| Moat | 7 / 15 | moat 4.7/10 | |
| Premium | 20 / 20 | implied volatility 58% | |
| Stability | 19 / 20 | 1.3M shares/day, $31.3B cap, beta 0.27 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Alnylam Pharmaceuticals, Inc. reports earnings on 29 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Alnylam Pharmaceuticals, Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ONC BeOne Medicines AG | 374.08 | 200.58 | -86% | 54Fair | $40.0B |
| ROIV Roivant Sciences Ltd. | 33.62 | 2.89 | -1063% | 44Weak | $24.3B |
| RVMD Revolution Medicines, Inc. | 193.52 | 0.8792 | -21911% | 42Weak | $41.5B |
| GMAB Genmab A/S | 37.82 | 44.48 | +15% | 73Good | $23.3B |
| UTHR United Therapeutics Corporation | 540.03 | 872.54 | +38% | 87Prime | $23.2B |
| INCY Incyte Corporation | 113.27 | 202.62 | +44% | 88Prime | $23.0B |
| BNTX BioNTech SE | 90.20 | 49.55 | -82% | 45Weak | $22.6B |
| INSM Insmed Incorporated | 99.21 | - | - | 45Weak | $21.7B |
| ARGX argenx SE | 846.27 | 796.62 | -6% | 65Good | $52.3B |
| EXEL Exelixis, Inc. | 62.83 | 105.86 | +41% | 94Prime | $15.8B |
| ASND Ascendis Pharma A/S | 226.62 | 267.55 | +15% | 70Good | $14.1B |
| NBIX Neurocrine Biosciences, Inc. | 136.95 | 236.51 | +42% | 87Prime | $13.9B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about ALNY
Is ALNY undervalued right now?
No: at 234.03 the stock trades 35% above the GLS average fair value of 173.82 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.
What is the Wheel Score of ALNY and what does it mean?
ALNY scores 59 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for ALNY?
173.82 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Alnylam Pharmaceuticals, Inc. report earnings next?
The next earnings report is due on 29 Oct 2026 (before the open), 13 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does ALNY have listed options, and how liquid are they?
Yes. The nightly snapshot found 786 listed contracts with 39,764 open interest across all expiries and implied volatility of 58% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.